-
Acorda Therapeutics Confirms It Entered Into A Patent Litigation Settlement Deal With Par Pharma
Thursday, January 21, 2016 - 10:29am | 185Read More...Acorda Therapeutics Inc (NASDAQ: ACOR) accused one of its rivals, Par Pharmaceutical, of infringing patents related to its multiple sclerosis treatment drug called Ampyra (dalfampridine) back in September, 2015. Par Pharmaceutical was seeking marketing approval from the FDA for its generic...
-
Acorda Therapeutics Could Be a Stock to Watch in 2013
Monday, February 4, 2013 - 4:21pm | 330Read More...Acorda Therapeutics (NASDAQ: ACOR) has been off to a hot start in 2013. The stock is already up around 16 percent on the year and shares are trading near 52-week high levels at roughly $29. The company has a market cap of $1.16 billion at current levels and the stock has risen over nine percent...
-
UPDATE: Aegis Capital Corp Initiates Buy on Acorda Therapeutics on Ampyra Visibility
Tuesday, August 21, 2012 - 1:07pm | 145Read More...Aegis Capital Corp initiated its rating on Acorda Therapeutics (NASDAQ: ACOR) with a Buy rating and a price target of $32 a share. Aegis Capital Corp commented, "We Believe Ampyra is an Undervalued Growth Asset. The patient population that Ampyra™ targets in the MS market is the largest of any...
-
Acorda Therapeutics Up 8.8% On Sales News (ACOR)
Monday, January 10, 2011 - 3:56pm | 233Read More...Shares of Acorda Therapeutics, Inc. (Nasdaq: ACOR) are trading up 8.8% at $30.09 per share during the Monday afternoon trading session. The company announced on Monday morning that its AMPYRA (dalfampridine) Extended Release Tablets, reached 4th quarter sales of $55.7 million and that its Zanaflex...
-
Acorda Therapeutics Shares Fall 4.4% Despite Results (ACOR)
Monday, November 1, 2010 - 12:45pm | 194Read More...Despite posting impressive financial results, shares of Acorda Therapeutics, Inc. (Nasdaq: ACOR) are currently down 4.4% at $25.85 per share during Monday afternoon trading. Today's trading range for shares of Acorda Therapeutics, Inc has been between $25.77 and $27.04 per share. The consensus...
